NASDAQ:NERV - Minerva Neurosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Minerva Neurosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.22 -0.27 (-3.18 %) (As of 01/29/2020 11:55 AM ET) Add Compare Today's Range$8.15Now: $8.22▼$8.5350-Day Range$5.59MA: $7.49▼$9.0752-Week Range$4.01Now: $8.22▼$9.23Volume9,946 shsAverage Volume327,472 shsMarket Capitalization$320.83 millionP/E RatioN/ADividend YieldN/ABeta1.67 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NERV Previous Symbol CUSIPN/A CIK1598646 Webhttp://www.minervaneurosciences.com/ Phone617-600-7373Debt Debt-to-Equity RatioN/A Current Ratio6.21 Quick Ratio6.21Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book3.54Profitability EPS (Most Recent Fiscal Year)($1.29) Net Income$-50,170,000.00 Net MarginsN/A Return on Equity-76.38% Return on Assets-44.37%Miscellaneous Employees13 Outstanding Shares39,030,000Market Cap$320.83 million Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive NERV News and Ratings via Email Sign-up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NERV Rates by TradingView Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions What is Minerva Neurosciences' stock symbol? Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV." How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences Inc (NASDAQ:NERV) announced its earnings results on Monday, November, 4th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.01. View Minerva Neurosciences' Earnings History. When is Minerva Neurosciences' next earnings date? Minerva Neurosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Minerva Neurosciences. What price target have analysts set for NERV? 4 Wall Street analysts have issued twelve-month price targets for Minerva Neurosciences' stock. Their forecasts range from $17.00 to $26.00. On average, they expect Minerva Neurosciences' stock price to reach $20.25 in the next year. This suggests a possible upside of 146.4% from the stock's current price. View Analyst Price Targets for Minerva Neurosciences. What is the consensus analysts' recommendation for Minerva Neurosciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Minerva Neurosciences. What are Wall Street analysts saying about Minerva Neurosciences stock? Here are some recent quotes from research analysts about Minerva Neurosciences stock: 1. According to Zacks Investment Research, "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The Company's pipeline will initially target the treatment of schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease. Its product candidates include MIN-101, MIN-117, MIN-202 and MIN-301. Minerva Neurosciences, Inc. is based in Cambridge, MA, United States. " (10/29/2019) 2. HC Wainwright analysts commented, "Valuation Our $22 price target for Minerva is based on our sum-of-the-parts NPV valuation based on each of the company’s pipeline assets. Our DCF model utilizes a discount rate of 11.5% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (5/31/2019) Has Minerva Neurosciences been receiving favorable news coverage? Press coverage about NERV stock has been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Minerva Neurosciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. View News Stories for Minerva Neurosciences. Are investors shorting Minerva Neurosciences? Minerva Neurosciences saw a drop in short interest in January. As of January 15th, there was short interest totalling 3,100,000 shares, a drop of 16.9% from the December 31st total of 3,730,000 shares. Based on an average daily trading volume, of 406,100 shares, the days-to-cover ratio is presently 7.6 days. Approximately 9.6% of the shares of the company are sold short. View Minerva Neurosciences' Current Options Chain. Who are some of Minerva Neurosciences' key competitors? Some companies that are related to Minerva Neurosciences include Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Rocket Pharmaceuticals (RCKT), ZEALAND PHARMA/S (ZEAL), Athenex (ATNX), Myovant Sciences (MYOV), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Karyopharm Therapeutics (KPTI), Phibro Animal Health (PAHC), Portola Pharmaceuticals (PTLA), Dermira (DERM), NextCure (NXTC), Revance Therapeutics (RVNC) and XBiotech (XBIT). What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include PTC Therapeutics (PTCT), Immunomedics (IMMU), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX), Synergy Pharmaceuticals (SGYP), Cara Therapeutics (CARA), Exelixis (EXEL), NovaBay Pharmaceuticals (NBY), Dynavax Technologies (DVAX) and Amicus Therapeutics (FOLD). Who are Minerva Neurosciences' key executives? Minerva Neurosciences' management team includes the folowing people: Dr. Rémy Luthringer, Exec. Chairman & CEO (Age 58)Mr. Geoffrey Robin Race, Exec. VP, CFO, Chief Bus. Officer & Company Sec. (Age 58)Dr. Michael Davidson, Chief Medical Officer (Age 69)Mr. Richard Russell, Pres (Age 55)Mr. Joseph Reilly, Sr. VP & COO (Age 44) Who are Minerva Neurosciences' major shareholders? Minerva Neurosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.07%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Joseph H Reilly, Remy Luthringer, Richard E Russell, Venture Associates L Index III and William F Doyle. View Institutional Ownership Trends for Minerva Neurosciences. Which major investors are buying Minerva Neurosciences stock? NERV stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer and William F Doyle. View Insider Buying and Selling for Minerva Neurosciences. How do I buy shares of Minerva Neurosciences? Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Minerva Neurosciences' stock price today? One share of NERV stock can currently be purchased for approximately $8.22. How big of a company is Minerva Neurosciences? Minerva Neurosciences has a market capitalization of $320.83 million. The biopharmaceutical company earns $-50,170,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Minerva Neurosciences employs 13 workers across the globe.View Additional Information About Minerva Neurosciences. What is Minerva Neurosciences' official website? The official website for Minerva Neurosciences is http://www.minervaneurosciences.com/. How can I contact Minerva Neurosciences? Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected] MarketBeat Community Rating for Minerva Neurosciences (NASDAQ NERV)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 306 (Vote Outperform)Underperform Votes: 252 (Vote Underperform)Total Votes: 558MarketBeat's community ratings are surveys of what our community members think about Minerva Neurosciences and other stocks. Vote "Outperform" if you believe NERV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NERV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: What is included in the gross domestic product?
